BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3186727)

  • 1. A serine peptidase responsible for the inactivation of endogenous cholecystokinin in brain.
    Rose C; Camus A; Schwartz JC
    Proc Natl Acad Sci U S A; 1988 Nov; 85(21):8326-30. PubMed ID: 3186727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection by serine peptidase inhibitors of endogenous cholecystokinin released from brain slices.
    Rose C; Camus A; Schwartz JC
    Neuroscience; 1989; 29(3):583-94. PubMed ID: 2739903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of a serine endopeptidase in the hydrolysis of exogenous cholecystokinin by brain slices.
    Camus A; Rose C; Schwartz JC
    Neuroscience; 1989; 29(3):595-602. PubMed ID: 2662053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A radioimmunoassay for the tripeptide Gly-Trp-Met, a major metabolite of endogenous cholecystokinin in brain.
    Rose C; Vargas F; Bourgeat P; Schwartz JC
    Neuropeptides; 1996 Jun; 30(3):231-5. PubMed ID: 8819147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a serine peptidase responsible for the inactivation of endogenous cholecystokinin in human brain.
    Rose C; Vargas F; Silhouette B; Devaux B; Schwartz JC
    Neuropeptides; 1995 Mar; 28(3):157-60. PubMed ID: 7791959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors.
    Steardo L; Knight M; Tamminga CA; Chase TN
    Neurosci Lett; 1985 Mar; 54(2-3):319-25. PubMed ID: 2986058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitors.
    Ganellin CR; Bishop PB; Bambal RB; Chan SM; Law JK; Marabout B; Luthra PM; Moore AN; Peschard O; Bourgeat P; Rose C; Vargas F; Schwartz JC
    J Med Chem; 2000 Feb; 43(4):664-74. PubMed ID: 10691692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase.
    Rose C; Vargas F; Facchinetti P; Bourgeat P; Bambal RB; Bishop PB; Chan SM; Moore AN; Ganellin CR; Schwartz JC
    Nature; 1996 Apr; 380(6573):403-9. PubMed ID: 8602240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tripeptidyl peptidase-I is essential for the degradation of sulphated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes.
    Warburton MJ; Bernardini F
    Neurosci Lett; 2002 Oct; 331(2):99-102. PubMed ID: 12361850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional metabolism of Met-enkephalin and cholecystokinin on intact ratbrain slices: characterization of specific peptidases.
    Konkoy CS; Davis TP
    J Neurochem; 1995 Dec; 65(6):2773-82. PubMed ID: 7595577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrolysis of the C-terminal octapeptide of cholecystokinin by rat kidney membranes: characterization of the cleavage by solubilized endopeptidase-24.11.
    Najdovski T; Collette N; Deschodt-Lanckman M
    Life Sci; 1985 Sep; 37(9):827-34. PubMed ID: 3897758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlapping regional distribution of CCK and TPPII mRNAs in Cynomolgus monkey brain and correlated levels in human cerebral cortex (BA 10).
    Radu D; Tomkinson B; Zachrisson O; Weber G; de Belleroche J; Hirsch S; Lindefors N
    Brain Res; 2006 Aug; 1104(1):175-82. PubMed ID: 16822484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
    Ganellin CR; Bishop PB; Bambal RB; Chan SM; Leblond B; Moore AN; Zhao L; Bourgeat P; Rose C; Vargas F; Schwartz JC
    J Med Chem; 2005 Nov; 48(23):7333-42. PubMed ID: 16279793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A.
    Migaud M; Durieux C; Viereck J; Soroca-Lucas E; Fournié-Zaluski MC; Roques BP
    Peptides; 1996; 17(4):601-7. PubMed ID: 8804068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the role of "enkephalinase" in cholecystokinin inactivation.
    Zuzel KA; Rose C; Schwartz JC
    Neuroscience; 1985 May; 15(1):149-58. PubMed ID: 3892359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of cholecystokinin, CCK-8, and CCK-33, 39 in rats, determined by a method based on enzyme digestion of gastrin before HPLC and RIA detection of CCK.
    Lindén A; Carlquist M; Hansen S; Uvnäs-Moberg K
    Gut; 1989 Feb; 30(2):213-22. PubMed ID: 2703143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunolocalization of tripeptidyl peptidase II, a cholecystokinin-inactivating enzyme, in rat brain.
    Facchinetti P; Rose C; Rostaing P; Triller A; Schwartz JC
    Neuroscience; 1999; 88(4):1225-40. PubMed ID: 10336132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cholecystokinin metabolism by membrane preparations from the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
    Medeiros Mdos S; Turner AJ
    Neurochem Int; 1994 Apr; 24(4):369-77. PubMed ID: 7914787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of acetylcholine release by cholecystokinin in striatum: receptor specificity; role of dopaminergic neuronal activity.
    Petkova-Kirova P; Giovannini MG; Kalfin R; Rakovska A
    Brain Res Bull; 2012 Dec; 89(5-6):177-84. PubMed ID: 22981453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain cholecystokinin-8 immunoreactivity in rats with experimental liver cirrhosis.
    Salerno F; Bonato C; Panerai AE; Martini A; Malesci A
    Life Sci; 1983 Jul; 33(4):377-81. PubMed ID: 6308371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.